Gadducci A, Brunetti I, Muttini M P, Fanucchi A, Dargenio F, Giannessi P G, Conte P F
Istituto di Clinica Ginecologia e Ostetrica, Università di Pisa, Italy.
Eur J Cancer. 1994;30A(10):1432-5. doi: 10.1016/0959-8049(94)00231-s.
Lonidamine (150 mg x 3 day orally, days 1-5) plus high dose epidoxorubicin (120 mg/m2 intravenously, day 3) was tested in 26 patients with refractory or recurrent epithelial ovarian cancer, to assess the anti-tumour activity and the toxicity of this combination of drugs. All patients were evaluable for toxicity and 24 for tumour response. Two complete responses (8.3%) and six partial responses (25.0%) were recorded for a total response rate of 33.3%. 6 of 8 responding patients were pretreated with anthracyclines. Stable disease was obtained in 7 patients (29.2%). Toxicity was acceptable; only 1 (3.8%) patient stopped chemotherapy because of a left ventricular ejection rate reduction > 20%. The most relevant side-effect was leucopenia (grade 3-4, 34.6%). In conclusion, the association of lonidamine and high-dose epidoxorubicin has promising activity as second-line treatment in patients with refractory or recurrent epithelial ovarian cancer.
对26例难治性或复发性上皮性卵巢癌患者进行了氯尼达明（口服，150毫克×3天，第1 - 5天）加用高剂量表柔比星（静脉注射，120毫克/平方米，第3天）的治疗，以评估该联合用药的抗肿瘤活性和毒性。所有患者均可评估毒性，24例可评估肿瘤反应。记录到2例完全缓解（8.3%）和6例部分缓解（25.0%），总缓解率为33.3%。8例缓解患者中有6例曾接受过蒽环类药物预处理。7例患者（29.2%）病情稳定。毒性反应可接受；只有1例（3.8%）患者因左心室射血率降低>20%而停止化疗。最主要的副作用是白细胞减少（3 - 4级，34.6%）。总之，氯尼达明与高剂量表柔比星联合作为难治性或复发性上皮性卵巢癌患者的二线治疗具有有前景的活性。
